عضو قدير
السهم معروف سابقا KFL وتغير اسمها الى LFTC
الشركة طبية وتنتج جهاز قياس الكولسترول مبيعاتها في تناقص والشركة عليها ديون
لكن الملفت شراء الانسايدر من شهر ونزل عليها امس خبر جيد
السهم سعره الان 7 سنت وهو اقل سعر خلال سنة وهي نقطة دعم قوية
السهم للمتابعة الجادة
عضو مميز
وخبر حلوووووووو
TC Lifestream Technologies Addresses Shareholder Concern Regarding Suspicious Stock Trading Activity and Share Price
June 29, 2004 06:30:00 (ET)
POST FALLS, Idaho, Jun 29, 2004 (BUSINESS WIRE) -- Lifestream Technologies, Inc. (LFTC, Trade), a leading developer and marketer of consumer cholesterol monitors and professional screening instruments, today released a letter to shareholders to address shareholder concern regarding the recent stock trading activity and share price of the Company's stock. The letter is distributed through this press release in its entirety.
Dear Fellow Shareholders:
I share everyone's disappointment in the recent share price decline. The Company has received a large number of emails and calls regarding this situation and it has been a challenge to return all the calls in a timely manner. Therefore, this communication is intended to address and assuage the concerns expressed in emails and over the phone.
The recent share price decline cannot be simply tied to any recent change in the Company's day-to-day operations since many consider the recent changes to be beneficial in nature. The Company is continuing operations according to its business strategy. With the addition of Walgreen's and the continuation of our awareness programs, we do not anticipate moving away from this strategy. We see nothing that accounts for the recent decline in market capitalization. In fact, operationally, the Company is in better shape today than 18 months ago.
We can only speculate as to any possible external cause for the share price decline. Lifestream recently became aware of the unauthorized listing on the Berlin-Bremen Stock Exchange. Many allegations have recently been discussed in the press regarding a possible arbitrage on U.S. markets leveraging stock that might not exist on the Berlin-Bremen Stock Exchange (BBSE). While these allegations have not been verified, the Company believes the potential downside of the exchange listing could be greater than any benefits being derived. As a result, the Company has sent written demand to the Berlin-Bremen Stock Exchange that it immediately cease trading in the Company's common stock and take whatever measures are necessary to completely delist the Company's common stock from the BBSE.
Our primary strategy to address the current share price decline is to stay on course and operationally grow the Company, building on the fundamentals of revenue growth and profitability. We are confident that, in time, our ongoing operational performance will overcome any external forces negatively impacting the Company's price per share.
Thank you for your ongoing support.
About Lifestream Technologies
The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.
The Company's product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual's efforts to improve compliance. Lifestream's products also integrate a smart card reader further supporting compliance by storing test results on an individual's personal health card for future retrieval, trend analysis and assessment.
Lifestream's monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern(TM) Personal Health Card(R), allowing multiple users the ability to store their personal results. Lifestream's products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream's products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.
This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and in particular statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in our most recent Registration Statement on Form SB-2 filed June 10, 2004, and in "Item 1 - Our Business," "Item 6 - Our Management's Discussion and Analysis," particularly the discussion under "Risk Factors - Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2003, both filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report, in the aforementioned Form SB-2 and Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.
للمتابعة
السعر 0.034
عضو قدير
ممدوح
توكلنا على الله وشرينا ب .0315
هل تتوقع صعود قريب لهذا السهم ؟؟ واين هدفه ؟
عضو مميز
خبر جديد اليوم
TC Lifestream Technologies` Shipments Double in Fourth Quarter 2004; With additional distribution and increasing awareness, Lifestream sees its business expanding in 2005
July 07, 2004 06:30:00 (ET)
POST FALLS, Idaho, Jul 7, 2004 (BUSINESS WIRE) -- Lifestream Technologies(TM) (LFTC, Trade), the leading manufacturer of home cholesterol monitors and professional screening devices, today announced that shipments in the fourth quarter were twice that of the same quarter ending 2003. The addition of a new retail account contributed to this increase in shipments.
"With the addition of a major retailer and our recent advertising and promotional programs, we are looking forward to an improvement in sales numbers," said Christopher Maus, Lifestream President and CEO. "An important component of improving our cash position is better management of our inventory as our sales increase. We expect to see an improvement in performance over the coming quarters with continued strong orders, increased margins, and cost containment. We continue to aggressively pursue the remaining distribution channels through the addition of new retail accounts."
"Lifestream's revenue recognition policy does not necessarily result in revenue recognition at the time product is shipped and, therefore, shipments may not be an indicator of the revenue to be reported on our financial statements. This increase in shipments is, however, a good indicator of our success in increasing distribution and creating awareness of our cholesterol monitor with consumers," stated Nikki Nessan, VP Finance.
About Lifestream Technologies
The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.
The Company's product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual's efforts to improve compliance. Lifestream's products also integrate a smart card reader further supporting compliance by storing test results on an individual's personal health card for future retrieval, trend analysis and assessment.
Lifestream's monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern(TM) Personal Health Card(R) allowing multiple users the ability to store their personal results. Lifestream's products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream's products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.
This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and in particular statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in our most recent Registration Statement on Form SB-2 filed June 10, 2004, and in "Item 1 - Our Business," "Item 6 - Our Management's Discussion and Analysis," particularly the discussion under "Risk Factors - Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2003, both filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report, in the aforementioned Form SB-2 and Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.
لم اقرأه لكن الشارت يوحي لي بان الخبر ايجابي
مع العلم ان الفوليوم هزيل جدا جدا ليوم
والله اعلم
عضو مميز
يستحق المتابعة الجادة
0.035
عضو مميز
مغري جدا جدا من وجهة نظري القاصرة
السعر 4 سنت
ولو انكسرت 5 سنت وهو ما اتوقعه فسوف تشاهدون الطيران المهول ان شاء الله
ممدوح
عضو مميز
سيولع هذا السهم
والسعر 0.045 الآن
والله اعلم
ممدوح
عضو مميز
الدخول على 4 سنت او اقل ارى انه جيد
والعلم عند الله
ولو يجي خبر وهو ما اتوقعه على هذه الشركة فسترون العجب ان شاء الله
موقوف
last 0.038
????
-15% .
Any news? thanks
موقوف
Can't believe it
I was putting a market order at 0.038 when he told me that it's 0.042/0.043
عضو مميز
اخي الاسباني
البيني لعبة توهتني كثيرا
لكنني رأيت بعض الاسهم التي ترتفع تعمل نفس حركة هذا السهم في بداية السوق حتى يصرفها الضعيف على الهامور ومن ثم تقلع
اتمنى ان تقلع
موقوف
اخوي ممدوح ، البيع والشراء على طاولات OTCBB يتلاعبون كثيرا ..
وبالتالى يجب ان تحاول سعرك ماركت وليس ليمت لتفاديهم ولكن بكل حذر..
تحية
LAST 0.047
عضو مميز
والحذر الحذر من اوامر الماركتالرسالة الأصلية كتبت بواسطة ELASBANI
وبالتالى يجب ان تحاول سعرك ماركت وليس ليمت لتفاديهم ولكن بكل حذر..
LAST 0.047
لانها تودي احيانا في ستين داهية
وعلى فكرة تراني استخدم امر اللمت ولكن بتفنن شوي
عضو قدير
السلام احلا شباب
الشارت يتكلم
موقوف
اهلا leo ..
بيع تحت 50 وان اجتازت وبصورة عادية اشتري من جديد ..
ان لم يرتفعوا بغاب كبير ويتركوا من خرجوا دون امكانية العودة للدخول..
بالتوفيق
عضو قدير
تسلم يا صديقي على هذا الشارت والتفصيل الــجداً واضح. أأيدك بأن القاعدة تقول البيع قبل 0.05 أو الشراء بعد تجاوزها. لكن الخوف من الأنفجار وخروجك من الحفلة مبكراً. والشارت يوحي بوجود حفلةً ما ووجباتها تطبخ على نار هادئه.
وبالنسبة لي أفضل التعزيز بعد تجاوز 0.05 على المغامرة بالخروج مبكراً.
موقوف
ايضا عين العقل ، لنأخذ شئ من الحفل..الرسالة الأصلية كتبت بواسطة leo
تسلم يا صديقي على هذا الشارت والتفصيل الــجداً واضح. أأيدك بأن القاعدة تقول البيع قبل 0.05 أو الشراء بعد تجاوزها. لكن الخوف من الأنفجار وخروجك من الحفلة مبكراً. والشارت يوحي بوجود حفلةً ما ووجباتها تطبخ على نار هادئه.
وبالنسبة لي أفضل التعزيز بعد تجاوز 0.05 على المغامرة بالخروج مبكراً.
اتمنى لك ذلك وراقب من اجله تحت 0.08 وخير ان شاء الله
عضو مميّز
الخبر قد يكون له تأثير اليوم
Lifestream Technologies, Inc. (OTCBB:LFTC), the leading manufacturer of home cholesterol monitors and professional screening devices, today announced that sales within a subset of its primary retail distribution channel are up 29% from the same period last year.
"With the implementation of our radio ad campaign beginning in March, as well as key promotional programs, Lifestream is realizing the preliminary impact of increasing consumer awareness for its products," noted Christopher Maus, Lifestream's President and CEO. "When compared to the same period last year, the subset's retail sales activity between mid March through mid May shows a 29% increase verifying that Lifestream's recent advertising and promotional activities are showing significant improvements within targeted retail segments. When compared with the subset's retail sales activity for January through mid March, Lifestream products realized a 19% increase. Generally, sales tend to flatten after the Christmas holiday, but continued retail sales increases reinforce the fact that Lifestream's efforts to raise awareness are having a material impact on retail growth
عضو مميز
خبر ممتاز وشارت رائع وانا متأمل خيرا ان شاء الله
عضو مميز
TC Lifestream Announces RxSchool`s Launch of National Pharmacy Education Program; Continuing Education Program Focuses on Increasing Patient Adherence Through Home Monitoring
July 27, 2004 06:30:00 (ET)
POST FALLS, Idaho, Jul 27, 2004 (BUSINESS WIRE) -- Lifestream Technologies, Inc. (LFTC, Trade), the leading manufacturer of home cholesterol monitors and professional screening devices, today announced that RxSchool is releasing a new pharmacy continuing education program designed to provide pharmacists with a greater understanding of the role home cholesterol monitoring plays in helping patients manage their cholesterol levels and improve overall patient compliance.
Steve Croke, President of RxSchool, stated, "Those patients on cholesterol-lowering drugs rarely stay on them long enough to derive the cardiovascular benefits the therapy can provide. The science is clear that one effective method is for patients to get regular feedback from self monitoring. To educate the pharmacist on this science is key to making a change in adherence. This is one of our best CE programs yet, and we are very excited about being able to provide pharmacists with an opportunity to adopt new tools in their effort to control heart disease."
"With only 30% of patients remaining on statin drugs after the first year, the value of improving patient adherence is undeniable," said Christopher Maus, Lifestream's President and CEO. "Statin drugs, considered by many to be extremely important for Americans' cardiovascular health, is the largest drug sector, exceeding $17 billion a year. Monitoring cholesterol at home is a proven method for enhancing patient adherence. It is very important that pharmacists understand the nature and value of patient self monitoring."
"We are very pleased that RxSchool, one the nation's premier providers for continuing education, has elected to provide this educational campaign for cholesterol management," stated Ed Siemens, Lifestream's COO. "These efforts will provide pharmacists throughout the U.S. with additional knowledge to support their patients in managing cholesterol through home monitoring. The role of home monitoring in the continuum of care is growing in importance. We are pleased that pharmacists, 120,000 strong, will have such a valuable educational resource."
عضو قدير
للرفع
ضوابط المشاركة
رد مع اقتباس
المفضلات